Firma Avisa Diagnostics Inc., Autor bei Presse-Blog

Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer

1. September 20212. September 2021 Firma Avisa Diagnostics Inc.Firmeninternalign, allergy, avisa, biomarker, clinical, financial, market, medical, merck, patients, research, securities, statements, treatment, with

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, is pleased to announce that the Company has hired Richard K. Murray, M.D., Mehr

Avisa Diagnostics to Participate at Upcoming Investor Events

9. Juli 202110. Juli 2021 Firma Avisa Diagnostics Inc.Allgemeinavisa, biomarker, clinical, financial, market, medical, networks, renmark, risks, roadshow, securities, statements, stellar, webinar, with

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, announced today that the Company will participate in several virtual investor events in Mehr

Avisa Diagnostics Appoints G. Michael Landis as Chief Financial Officer

22. Juni 202123. Juni 2021 Firma Avisa Diagnostics Inc.Firmeninternavisa, biomarker, clinical, deloitte, financial, landis, market, medical, patients, securities, security, statements, strong, treatment, with

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in post-COVID-19 long haulers and for ventilator-associated pneumonia, is pleased to announce that G. Michael Mehr

Avisa Diagnostics to Participate in Renmark’s Virtual Non-Deal Roadshow Series on June 17, 2021

17. Juni 202117. Juni 2021 Firma Avisa Diagnostics Inc.Allgemeinampa, avisa, biomarker, clinical, company, covid, diagnostics, financial, google, may, medical, roadshow, series, virtual, with

Avisa Diagnostics Inc. (CSE: AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in post-COVID-19 long haulers and for ventilator-associated pneumonia, announced today that the Company will Mehr

Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

18. Mai 202118. Mai 2021 Firma Avisa Diagnostics Inc.Allgemeinabt, billion, bronchial, cad, colonization, copd, forward, its, looking, market, patients, quarter, scs, securities, statements

. – Public Listing offers Access to CAD 52 Million from Share Subscription and Drawdown Agreement, Sufficient Funding to Complete Development and Launch Avisa BreathTest™ – Pivotal Trials Planned in Post-COVID-19 Long Haulers and Ventilator-Associated Pneumonia Avisa Diagnostics Inc. (Avisa) Mehr

Autor: Firma Avisa Diagnostics Inc.